Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              ViGeneron

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              ViGeneron Signs Global Collaboration Agreement for Ophthalmic Gene Therapy Development

              Contact the Supplier

              Lead Product(s): VG801

              Therapeutic Area: Ophthalmology Product Name: VG801

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Biogen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 05, 2021

              Details:

              The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.

              Eyevensys

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa

              Contact the Supplier

              Lead Product(s): EYS611

              Therapeutic Area: Ophthalmology Product Name: EYS611

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2020

              Details:

              Eyevensys is developing EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit patients diagnosed with RP, as well as other degenerative retinal diseases, including late stage, dry age-related macular degeneration and glaucoma.

              PharmaCompass__DigitalAd